Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBITDA Margin for 16 consecutive years, with 0.89% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 7587.0% to 0.89% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8.03% through Dec 2025, up 3970.0% year-over-year, with the annual reading at 8.03% for FY2025, 3970.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 0.89% at Anika Therapeutics, up from 9.03% in the prior quarter.
  • The five-year high for EBITDA Margin was 2151.74% in Q4 2023, with the low at 98.8% in Q3 2024.
  • Average EBITDA Margin over 5 years is 99.74%, with a median of 9.16% recorded in 2025.
  • The sharpest move saw EBITDA Margin surged 201346bps in 2023, then plummeted -222673bps in 2024.
  • Over 5 years, EBITDA Margin stood at 17.29% in 2021, then surged by 900bps to 138.28% in 2022, then soared by 1456bps to 2151.74% in 2023, then crashed by -103bps to 74.99% in 2024, then surged by 101bps to 0.89% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 0.89%, 9.03%, and 9.29% for Q4 2025, Q3 2025, and Q2 2025 respectively.